The prevalence of depressive and anxiety symptoms and their associations with quality of life among clinically stable older patients with psychiatric disorders during the COVID-19 pandemic

Wen Li, Na Zhao, Xiaona Yan, Siyun Zou, Huan Wang, Yulong Li, Xiuying Xu, Xiangdong Du, Lan Zhang, Qinge Zhang, Teris Cheung, Gabor S Ungvari, Chee H Ng, Yu-Tao Xiang, Wen Li, Na Zhao, Xiaona Yan, Siyun Zou, Huan Wang, Yulong Li, Xiuying Xu, Xiangdong Du, Lan Zhang, Qinge Zhang, Teris Cheung, Gabor S Ungvari, Chee H Ng, Yu-Tao Xiang

Abstract

The impact of the COVID-19 pandemic on clinically stable older patients with psychiatric disorders is unclear. This study examined the prevalence of depressive and anxiety symptoms, and their associations with quality of life (QOL) in clinically stable older patients with psychiatric disorders during the COVID-19 pandemic. This was a multicenter, cross-sectional study. Depressive and anxiety symptoms, insomnia, pain, and QOL were assessed with standardized instruments. A total of 1063 patients were included. The prevalence of depressive and anxiety symptoms, and combined depressive and anxiety symptoms were 62.3% (95%CI = 59.4-65.2%), 52.4% (95%CI = 49.3-55.4%), and 45.9% (95%CI = 42.9-48.9%), respectively. Patients with depressive and anxiety symptoms had significantly lower QOL than those without (P < 0.01). Binary logistic regression analyses revealed that having depressive symptoms was positively associated with more severe insomnia (OR = 1.29, P < 0.01) and pain (OR = 1.14, P < 0.01), and was negatively associated with other psychiatric diagnoses (except for major depressive disorder, schizophrenia, and organic mental disorder; OR = 0.50, P < 0.01), while having anxiety symptoms was positively associated with severe physical diseases (OR = 1.57, P = 0.02), poor adherence to treatment (OR = 1.50, P < 0.01), and more severe insomnia (OR = 1.15, P < 0.01) and pain (OR = 1.11, P < 0.01). Having combined depression and anxiety symptoms was positively associated with poor adherence to treatment (OR = 1.42, P = 0.02) and more severe insomnia (OR = 1.19, P < 0.01) and pain (OR = 1.15, P < 0.01), and was negatively associated with the diagnosis of schizophrenia (OR = 0.50, P = 0.04) and others (OR = 0.53, P < 0.01). Depressive and anxiety symptoms were common in clinically stable older patients with psychiatric disorders during the COVID-19 pandemic. Considering the negative impact of these symptoms on QOL, regular screening and appropriate treatment are recommended for this population.

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard (2020).
    1. Yang Y, et al. Mental health services for older adults in China during the COVID-19 outbreak. Lancet Psychiatry. 2020;7:e19. doi: 10.1016/S2215-0366(20)30079-1.
    1. Pormohammad A, et al. Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: a systematic review and meta-analysis. Micro. Pathog. 2020;147:104390. doi: 10.1016/j.micpath.2020.104390.
    1. Shahid Z, et al. COVID-19 and older adults: what we know. J. Am. Geriatr. Soc. 2020;68:926–929. doi: 10.1111/jgs.16472.
    1. Du R-H, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur. Respir. J. 2020;55:2000524. doi: 10.1183/13993003.00524-2020.
    1. Hao F, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav. Immun. 2020;87:100–106. doi: 10.1016/j.bbi.2020.04.069.
    1. González-Blanco L, et al. COVID-19 lockdown in people with severe mental disorders in Spain: do they have a specific psychological reaction compared with other mental disorders and healthy controls? Schizophr. Res. 2020;223:192–198. doi: 10.1016/j.schres.2020.07.018.
    1. Xiang YT, Ng CH, Yu X, Wang G. Rethinking progress and challenges of mental health care in China. World Psychiatry. 2018;17:231. doi: 10.1002/wps.20500.
    1. Xiang Y-T, Yu X, Sartorius N, Ungvari GS, Chiu HF. Mental health in China: challenges and progress. Lancet. 2012;380:1715–1716. doi: 10.1016/S0140-6736(11)60893-3.
    1. Bendixen AB, Engedal K. Anxiety among older psychiatric patients: a hidden comorbidity? Aging Ment. Health. 2016;20:1131–1138. doi: 10.1080/13607863.2015.1063106.
    1. Beekman AT, et al. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am. J. Psychiatry. 2000;157:89–95. doi: 10.1176/ajp.157.1.89.
    1. Prina A, Ferri C, Guerra M, Brayne C, Prince M. Co-occurrence of anxiety and depression amongst older adults in low-and middle-income countries: findings from the 10/66 study. Psychol. Med. 2011;41:2047. doi: 10.1017/S0033291711000444.
    1. Schoevers RA, Deeg DJH, van Tilburg W, Beekman ATF. Depression and generalized anxiety disorder: co-occurrence and longitudinal patterns in elderly patients. Am. J. Geriatr. Psychiatry. 2005;13:31–39. doi: 10.1097/00019442-200501000-00006.
    1. Gulpers B, et al. Anxiety as a predictor for cognitive decline and dementia: a systematic review and meta-analysis. Am. J. Geriatr. Psychiatry. 2016;24:823–842. doi: 10.1016/j.jagp.2016.05.015.
    1. Wei J, et al. Late-life depression and cognitive function among older adults in the U.S.: The National Health and Nutrition Examination Survey, 2011–2014. J. Psychiatr. Res. 2019;111:30–35. doi: 10.1016/j.jpsychires.2019.01.012.
    1. Roy-Byrne PP, et al. Anxiety disorders and comorbid medical illness. Gen. Hosp. Psychiatry. 2008;30:208–225. doi: 10.1016/j.genhosppsych.2007.12.006.
    1. Holvast F, et al. Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study. Fam. Pract. 2017;34:539–545. doi: 10.1093/fampra/cmx018.
    1. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines (World Health Organization, Geneva, 1992).
    1. Avendano M, Glymour M, Banks J, Mackenbach J. Health disadvantage in US adults aged 50 to 74 years: a comparison of the health of rich and poor Americans with that of Europeans. Am. J. Public Health. 2009;99:540–548. doi: 10.2105/AJPH.2008.139469.
    1. Dong M, et al. Antipsychotic polypharmacy in older adult asian patients with schizophrenia: research on Asian psychotropic prescription pattern. J. Geriatr. Psychiatry Neurol. 2019;32:304–311. doi: 10.1177/0891988719862636.
    1. Xiang Y-T, et al. Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007;31:756–760. doi: 10.1016/j.pnpbp.2007.01.013.
    1. Lobana A, Mattoo SK, Basu D, Gupta N. Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatr. Scandinavica. 2001;104:51–55. doi: 10.1034/j.1600-0447.2001.104001051.x.
    1. Hajian-Tilaki K. Sample size estimation in epidemiologic studies. Casp. J. Intern. Med. 2011;2:289.
    1. Shi L, et al. Prevalence of and risk factors associated with mental health symptoms among the general population in China during the Coronavirus Disease 2019 Pandemic. JAMA Netw. Open. 2020;3:e2014053–e2014053. doi: 10.1001/jamanetworkopen.2020.14053.
    1. Bo HX, et al. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychol. Med. 2020;27:1–2. doi: 10.1017/S0033291720000999.
    1. Luo H, Lie Y, Prinzen FW. Surveillance of COVID-19 in the general population using an online questionnaire: report from 18,161 respondents in China. JMIR Public Health Surveill. 2020;6:e18576. doi: 10.2196/18576.
    1. Zhou J, Liu L, Xue P, Yang X, Tang X. Mental health response to the COVID-19 outbreak in China. Am. J. Psychiatry. 2020;177:574–575. doi: 10.1176/appi.ajp.2020.20030304.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ‐9: validity of a brief depression severity measure. J. Gen. Intern. Med. 2001;16:606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Chen M, Sheng L, Qu S. Diagnostic test of screening depressive disorder in general hospital with the Patient Health Questionnaire (in Chinese) Chin. Ment. Health. 2015;29:241–245.
    1. Wang W, et al. Reliability and validity of the Chinese version of the Patient Health Questionnaire (PHQ-9) in the general population. Gen. Hosp. Psychiatry. 2014;36:539–544. doi: 10.1016/j.genhosppsych.2014.05.021.
    1. Kroenke K, Spitzer RL, Williams JB, Löwe B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen. Hosp. Psychiatry. 2010;32:345–359. doi: 10.1016/j.genhosppsych.2010.03.006.
    1. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch. Intern. Med. 2006;166:1092–1097. doi: 10.1001/archinte.166.10.1092.
    1. He X-Y, Li C-B, Qian J, Cui H-S, Wu W-Y. Study on the reliability and validity of Generalized Anxiety Scale in general hospitals (in Chinese) Shanghai Arch. Psychiatry. 2010;22:200–203.
    1. Morin, C. M. Insomnia: Psychological Assessment and Management (Guilford Press, 1993).
    1. Bai C, Daihong J, Chen L, Liang L, Wang C. Reliability and validity of Insomnia Severity Index in clinical insomnia patients (in Chinese) Chin. J. Practical Nurs. 2018;34:2182–2186.
    1. Smith MT, Wegener ST. Measures of sleep: the Insomnia Severity Index, Medical Outcomes Study (MOS) Sleep Scale, Pittsburgh Sleep Diary (PSD), and Pittsburgh Sleep Quality Index (PSQI) Arthritis Care Res. 2003;49:S184–S196. doi: 10.1002/art.11409.
    1. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr. Nurs. 1988;14:9–17.
    1. Haefeli M, Elfering A. Pain assessment. Eur. Spine J. 2006;15:S17–S24. doi: 10.1007/s00586-005-1044-x.
    1. Boonstra AM, et al. Cut-off points for mild, moderate, and severe pain on the numeric rating scale for pain in patients with chronic musculoskeletal pain: variability and influence of sex and catastrophizing. Front Psychol. 2016;7:1466–1466. doi: 10.3389/fpsyg.2016.01466.
    1. Harper A, Power M, Grp W. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol. Med. 1998;28:551–558. doi: 10.1017/S0033291798006667.
    1. Fang JQ, Hao YA. Reliability and validity for Chinese Version of WHO Quality of Life Scale (in Chinese) Chin. Ment. Health J. 1999;13:203–209.
    1. Xia P, Li N, Hau K-T, Liu C, Lu Y. Quality of life of Chinese urban community residents: a psychometric study of the mainland Chinese version of the WHOQOL-BREF. BMC Med. Res. Methodol. 2012;12:37. doi: 10.1186/1471-2288-12-37.
    1. Zhou S-J, et al. Prevalence and socio-demographic correlates of psychological health problems in Chinese adolescents during the outbreak of COVID-19. Eur. Child Adolesc. Psychiatry. 2020;29:749–758. doi: 10.1007/s00787-020-01541-4.
    1. Orhan M, et al. The relationship between cognitive and social functioning in older patients with bipolar disorder. J. Affect Disord. 2018;240:177–182. doi: 10.1016/j.jad.2018.07.055.
    1. Shimada H, et al. Depressive symptoms and cognitive performance in older adults. J. Psychiatr. Res. 2014;57:149–156. doi: 10.1016/j.jpsychires.2014.06.004.
    1. Murante T, Cohen CI. Cognitive functioning in older adults with schizophrenia. Focus (Am. Psychiatr. Publ.) 2017;15:26–34.
    1. Zainal NZ, Kalita P, Herr KJ. Cognitive dysfunction in Malaysian patients with major depressive disorder: a subgroup analysis of a multicountry, cross-sectional study. Asia Pac. Psychiatry. 2019;11:e12346. doi: 10.1111/appy.12346.
    1. Wang, H., Yu, E. & Tang, Y. Psychological Support and Counselling for Older Adults During the Outbreak of COVID-19[M] (Chinese Medical Multimedia Press, Beijing, 2020).
    1. Chinese Society of Geriatric Psychiatry, Alzheimer’s Disease Chinese of Chinese Aging Well Association (CAWA/ADC), Psychogeriatric Interest Group of Chinese Society of Psychiatry, Geriatric Psychiatry Working Group of Chinese Psychiatrists Association & Aging Mental Health Committee of Chinese Association for Mental Health. Expert recommendations on mental health and psychosocial support for persons with cognitive disorders and their caregivers during the COVID-19 outbreak (in Chinese). Chin. J. Psychiatry53, 89–94 (2020).
    1. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry. 2005;62:617–627. doi: 10.1001/archpsyc.62.6.617.
    1. Hettema JM, Kuhn JW, Prescott CA, Kendler KS. The impact of generalized anxiety disorder and stressful life events on risk for major depressive episodes. Psychol. Med. 2006;36:789–795. doi: 10.1017/S0033291706007367.
    1. Wetherell JL, Gatz M, Pedersen NL. A longitudinal analysis of anxiety and depressive symptoms. Psychol. Aging. 2001;16:187. doi: 10.1037/0882-7974.16.2.187.
    1. Molina E, et al. Polymorphic variation at the serotonin 1-A receptor gene is associated with comorbid depression and generalized anxiety. Psychiatr. Genet. 2011;21:195–201. doi: 10.1097/YPG.0b013e3283457a48.
    1. Etkin A, Schatzberg AF. Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. Am. J. Psychiatry. 2011;168:968–978. doi: 10.1176/appi.ajp.2011.10091290.
    1. Jaussent I, et al. Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly. Sleep. 2011;34:1103–1110. doi: 10.5665/SLEEP.1170.
    1. Hertenstein E, et al. Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep. Med. Rev. 2019;43:96–105. doi: 10.1016/j.smrv.2018.10.006.
    1. Sunderajan P, et al. Insomnia in patients with depression: a STAR*D report. CNS Spectr. 2010;15:394–404. doi: 10.1017/S1092852900029266.
    1. Khan IW, Juyal R, Shikha D, Gupta R. Generalized anxiety disorder but not depression is associated with insomnia: a population based study. Sleep. Sci. 2018;11:166–173. doi: 10.5935/1984-0063.20180031.
    1. de Lecea L, Carter ME, Adamantidis A. Shining light on wakefulness and arousal. Biol. Psychiatry. 2012;71:1046–1052. doi: 10.1016/j.biopsych.2012.01.032.
    1. Krysta K, Krzystanek M, Bratek A, Krupka-Matuszczyk I. Sleep and inflammatory markers in different psychiatric disorders. J. Neural Transm. 2017;124:179–186. doi: 10.1007/s00702-015-1492-3.
    1. Fayaz A, Croft P, Langford R, Donaldson L, Jones G. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open. 2016;6:e010364. doi: 10.1136/bmjopen-2015-010364.
    1. Henschke N, Kamper SJ, Maher CG. The epidemiology and economic consequences of pain. Mayo Clin. Proc. 2015;90:139–147. doi: 10.1016/j.mayocp.2014.09.010.
    1. Velly AM, Mohit S. Epidemiology of pain and relation to psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2018;87:159–167. doi: 10.1016/j.pnpbp.2017.05.012.
    1. Gerrits MMJG, et al. Impact of pain on the course of depressive and anxiety disorders. Pain. 2012;153:429–436. doi: 10.1016/j.pain.2011.11.001.
    1. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization study in primary care. JAMA. 1998;280:147–151. doi: 10.1001/jama.280.2.147.
    1. Fillingim RB, et al. Psychological factors associated with development of TMD: the OPPERA prospective cohort study. J. Pain. 2013;14:T75–T90. doi: 10.1016/j.jpain.2013.06.009.
    1. Aggarwal VR, Macfarlane GJ, Farragher TM, McBeth J. Risk factors for onset of chronic oro-facial pain–results of the North Cheshire oro-facial pain prospective population study. Pain. 2010;149:354–359. doi: 10.1016/j.pain.2010.02.040.
    1. Lurie I, Levine SZ. Meta-analysis of dropout rates in SSRIs versus placebo in randomized clinical trials of PTSD. J. Nerv. Ment. Dis. 2010;198:116–124. doi: 10.1097/NMD.0b013e3181cc41b6.
    1. Taylor S, Abramowitz JS, McKay D. Non-adherence and non-response in the treatment of anxiety disorders. J. Anxiety Disord. 2012;26:583–589. doi: 10.1016/j.janxdis.2012.02.010.
    1. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen. Hosp. Psychiatry. 2007;29:147–155. doi: 10.1016/j.genhosppsych.2006.11.005.
    1. Härter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and physical illness. Eur. Arch. Psychiatry Clin. Neurosci. 2003;253:313–320. doi: 10.1007/s00406-003-0449-y.
    1. Villarreal-Zegarra D, Bernabe-Ortiz A. Association between arterial hypertension and depressive symptoms: results from population-based surveys in Peru. Asia Pac. Psychiatry. 2020;12:e12385. doi: 10.1111/appy.12385.
    1. Hatoum HT, Kong SX, Kania CM, Wong JM, Mendelson WB. Insomnia, health-related quality of life and healthcare resource consumption. Pharmacoeconomics. 1998;14:629–637. doi: 10.2165/00019053-199814060-00004.
    1. Zainal NH, Newman MG. Executive function and other cognitive deficits are distal risk factors of generalized anxiety disorder 9 years later. Psychol. Med. 2018;48:2045. doi: 10.1017/S0033291717003579.
    1. Ng P, Tsun A, Su S, Young D. Cognitive behavioral intervention in the Chinese cultural context: a case report. Asia Pac. Psychiatry. 2013;5:205–211. doi: 10.1111/appy.12092.
    1. Zhao XR, et al. Mindfulness-based cognitive therapy is associated with distinct resting-state neural patterns in patients with generalized anxiety disorder. Asia Pac. Psychiatry. 2019;11:e12368. doi: 10.1111/appy.12368.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere